Envestnet Asset Management Inc. Increases Position in Cencora, Inc. (NYSE:COR)

Envestnet Asset Management Inc. lifted its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 0.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 589,072 shares of the company's stock after acquiring an additional 3,546 shares during the period. Envestnet Asset Management Inc. owned approximately 0.30% of Cencora worth $132,353,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Whittier Trust Co. boosted its holdings in Cencora by 0.6% during the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after acquiring an additional 44 shares during the last quarter. Shepherd Financial Partners LLC boosted its holdings in Cencora by 0.9% during the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock worth $1,223,000 after purchasing an additional 46 shares during the last quarter. WASHINGTON TRUST Co boosted its holdings in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares during the last quarter. JFS Wealth Advisors LLC increased its stake in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares during the last quarter. Finally, Cullen Frost Bankers Inc. increased its stake in Cencora by 1.1% in the 4th quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock valued at $1,003,000 after buying an additional 47 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Analyst Ratings Changes

Several research firms have recently issued reports on COR. JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Evercore ISI upped their price objective on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Wells Fargo & Company raised their target price on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. Bank of America boosted their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday. Finally, StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and a consensus price target of $284.20.

Cencora Stock Performance

Shares of COR traded up $5.31 during trading hours on Friday, hitting $284.46. The company's stock had a trading volume of 1,509,188 shares, compared to its average volume of 1,509,347. The company has a market cap of $55.16 billion, a price-to-earnings ratio of 40.46, a PEG ratio of 1.31 and a beta of 0.55. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The business has a 50 day simple moving average of $260.27 and a two-hundred day simple moving average of $245.16. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $296.65.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.77%. Cencora's dividend payout ratio is currently 31.29%.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the transaction, the chairman now directly owns 317,913 shares of the company's stock, valued at $85,680,732.63. This trade represents a 4.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares in the company, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock valued at $8,034,778 in the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.